VTE Prophylaxis After Hip Arthroplasty

Recommended Pharmacological Options

The American College of Cardiology recommends prophylaxis with low-molecular-weight heparin (LMWH) started 12 hours before or after surgery and continued for 10-14 days, with extension up to 35 days to reduce the risk of venous thromboembolism 1, 2
LMWH is the preferred first-line option for VTE prophylaxis after hip arthroplasty, with enoxaparin 30 mg twice daily or 40 mg once daily being the most widely used regimen 1, 3
Fondaparinux 2.5 mg subcutaneously once daily is an effective alternative, with a reduced dose of 1.5 mg daily for patients with renal impairment (CrCl 30-50 mL/min) 1
Unfractionated heparin 5000 U subcutaneously twice or thrice daily can be used when LMWH is contraindicated 1, 2
Adjusted-dose warfarin (target INR 2.0-3.0) is an option, but not preferred over newer agents 1

A minimum duration of 10-14 days of prophylaxis is recommended for all patients undergoing hip arthroplasty 1, 2
Extended prophylaxis up to 35 days is recommended, especially for patients at high risk of VTE 1, 2

For LMWH, initiation 12 hours before or after surgery is recommended 1
For rivaroxaban, initiation 6-10 hours after surgery once hemostasis is achieved is recommended 1
For fondaparinux, initiation 6-8 hours after surgery once hemostasis is established is recommended 1

Intermittent pneumatic compression (IPC) devices should be used in addition to pharmacological prophylaxis for a goal of 18 hours daily 2
For patients at high risk of bleeding, mechanical prophylaxis with IPC may be used alone until bleeding risk diminishes 2, 3
Early ambulation should be encouraged as part of a multimodal approach 2

Patients with renal impairment (CrCl <30 mL/min) should avoid LMWH and fondaparinux, and consider unfractionated heparin or adjusted-dose warfarin 1
For patients who cannot use heparins, consider aspirin, fondaparinux, or IPC 2
Cancer patients should receive extended prophylaxis with LMWH for 4 weeks 2

Approximately 42-58% of at-risk patients do not receive appropriate VTE prophylaxis, despite clear guidelines 1
Individualized risk assessment using validated tools (like Caprini score) helps determine patients who would benefit most from extended prophylaxis 3

For patients with renal impairment (creatinine clearance <30 ml/min), the dose of enoxaparin should be reduced to 30 mg subcutaneously once daily, as recommended by urology guidelines 4, 5
For patients with body weight >150 kg, consider increasing the prophylaxis dose to 40 mg subcutaneously every 12 hours, based on evidence from urology research 4, 5

Mechanical prophylaxis with intermittent pneumatic compression devices should be used in addition to pharmacological prophylaxis with enoxaparin, as supported by urology studies 4, 5
Early ambulation should be encouraged as part of the prophylactic approach to prevent DVT, according to urology guidelines 4, 5

For patients with a history of heparin-induced thrombocytopenia, special testing may be indicated before using enoxaparin, as recommended by urology experts 4, 5
For patients requiring epidural or spinal anesthesia, enoxaparin should be held for 24 hours before catheter manipulation and resumed no earlier than 2 hours after catheter removal, based on urology guidelines 4, 5
In selected very high-risk patients, post-discharge prophylaxis with enoxaparin or warfarin should be considered, as suggested by urology research 4, 5

The timing of initiation of enoxaparin must balance thromboprophylaxis benefits against bleeding risk, as noted in urology studies 4

The American College of Cardiology recommends enoxaparina as the preferred agent, with a dosage of 40 mg subcutaneously once daily or 30 mg twice daily, demonstrating superiority over unfractionated heparin in reducing venous thrombosis and proximal venous thrombosis 6
Semuloparina demonstrated superiority over enoxaparina with rates of venous thromboembolism or mortality of 6.3% versus 11.1% (OR 0.54, p<0.001) 7

A meta-analysis of studies comparing low molecular weight heparin (LMWH) with unfractionated heparin showed a common odds ratio of 0.40 for proximal venous thrombosis favoring LMWH 6